Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Has multicentric Castleman's disease~* Have previously been enrolled in Study C0328T03 or CNTO328MCD2001 (either treatment arm)~* Have had their last administration of study treatment (siltuximab or placebo) less than 6 weeks (window of plus 2 weeks) prior to first dose~* Patients must not have had disease progression while receiving siltuximab. For those patients originally assigned to placebo in the CNTO328MCD2001 study, patients who have received less than 4 months of siltuximab following crossover will also be eligible~* Have adequate clinical laboratory parameters within 2 weeks prior to the first dose of siltuximab for this study~Exclusion Criteria:~* Unmanageable toxicity, an adverse event, progression of disease, or withdrawal of consent as reason for discontinuing treatment from previous sponsor-initiated siltuximab study~* Vaccination with live, attenuated vaccines within 4 weeks of first dose of this study~* Known unmanageable allergies, hypersensitivity, intolerance to monoclonal antibodies, to murine, chimeric, human proteins or their excipients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Siltuximab (Type: EXPERIMENTAL): Siltuximab 11 mg/kg, intravenous infusion, given as a 1-hour infusion every 3 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).